查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000853

新型藥物遞送系統市場：按產品類型、給藥途徑、技術、應用和最終用戶分類－2026-2032年全球市場預測

Novel Drug Delivery Systems Market by Product Type, Route Of Administration, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，新型藥物輸送系統市場價值將達到 164 億美元，到 2026 年將成長至 179.5 億美元，到 2032 年將達到 311.3 億美元，複合年成長率為 9.57%。

主要市場統計數據
基準年 2025 164億美元
預計年份：2026年 179.5億美元
預測年份：2032年 311.3億美元
複合年成長率 (%) 9.57%

全面概述跨學科創新和以患者為中心的設計如何重新定義新型藥物輸送平台的目的和潛力。

隨著分子水平創新與先進材料科學和以患者為中心的護理模式相融合，藥物遞送領域正在經歷根本性的變革。新型藥物遞送系統涵蓋了從吸入裝置和注射劑到經皮吸收貼片以及最先進的微奈米載體等多種平台，每一種都旨在提高治療指數、患者依從性和靶向生物分佈。本執行摘要介紹了影響生物製藥、醫療技術和專業醫療設備公司發展重點和投資策略的關鍵技術、監管和商業性轉折點。

精準標靶、數位整合和策略夥伴關係如何重塑創造臨床價值和實現先進藥物遞送商業化的途徑？

多項變革正在加速藥物遞送技術的演進，並重新定義新治療方法的成功標準。首先，奈米顆粒、脂質奈米顆粒系統和植入式裝置實現的精準標靶遞送已從概念驗證發展到實際臨床應用階段，從而能夠在病灶部位提高治療藥物濃度，同時降低全身暴露。這項技術的成熟與監管機構對複合製劑和新型輔料的日益認可相吻合，使得更具雄心的製劑和整合式裝置解決方案成為可能。

2025 年美國關稅調整對採購、製造在地化和供應鏈韌性的營運和策略影響。

2025年美國關稅環境對整個生命科學供應鏈造成了微妙的營運和戰略壓力，從多方面影響零件採購、製造地選擇和成本結構。針對特定原料和醫療設備零件的關稅措施提高了某些聚合物、特殊脂質和用於連網型設備的電子子系統的進口成本。這種變化促使那些先前依賴全球化成本最佳化籌資策略的製造商重新評估其營運模式。

基於可操作的細分情報進行精確的策略定位，將給藥途徑、底層技術、治療應用、產品類型和最終用戶管道連結起來。

細分市場層面的趨勢揭示了不同的機會和技術限制，這些都應體現在研發優先事項和商業規劃中。就給藥途徑而言，吸入平台（包括乾粉吸入器和霧化器）正在被重新開發，以支持生物製藥和局部肺部治療；而注射製劑（包括肌肉注射、靜脈注射和皮下注射）仍然是全身性生物製藥和長效緩釋製劑的核心。鼻腔給藥（透過滴鼻劑和滴鼻劑）是快速實施中樞神經系統 (CNS) 和黏膜免疫策略的一種很有前景的途徑；而口服給藥（透過膠囊、液體和片劑）在穩定性和患者依從性方面仍在不斷最佳化。經經皮給藥（透過凝膠和貼片）在治療慢性疾病、穩定狀態以及需要穩定血漿濃度曲線的療法中越來越受到關注。

美洲、歐洲、中東、非洲和亞太地區的監管環境、還款狀況和製造業趨勢將如何影響發展重點和市場進入順序？

區域趨勢決定了新型給藥系統的研發、生產和商業化的優先事項。在美洲，生技藥品和植入式醫療設備創新叢集與完善的報銷機制並存，加速了產品的普及應用。然而，供應鏈和關稅方面的考量使得本地化生產和監管協調至關重要。歐洲、中東和非洲的情況則呈現多樣性。在一些歐洲市場，成熟的監管管道和集中採購體係有利於先進醫療設備和複合產品的發展，而該地區的新興市場則可能優先考慮成本效益高、易於操作的解決方案和分散式醫療模式。亞太地區擁有龐大的患者群體、不斷擴展的臨床試驗能力以及快速擴大產業規模的潛力，因此蘊藏著豐富的機會。但進入亞太市場需要仔細考慮各國具體的監管細則和對在地化生產的期望。

透過整合技術堆疊、策略合作夥伴關係以及對真實世界數據和卓越製造的關注，實現競爭差異化。

新型藥物遞送系統領域的競爭格局呈現出多元化的特點，既有成熟的製藥公司，也有醫療設備專家和敏捷的技術創新者。主要企業憑藉垂直整合的能力脫穎而出，這些能力涵蓋製劑科學、器械工程和生產規模化，從而能夠快速從概念階段過渡到臨床試驗階段。從許可和共同開發契約到股權投資，各種策略聯盟是獲取互補能力的常用手段，尤其是在奈米顆粒工程、微針製造和數位健康整合等領域。

生命科學產業的領導者需要採取切實可行、優先排序和具有戰略意義的行動，以協調研發、供應鏈韌性和創造永續應用的商業性證據。

行業領導者應採取一系列優先行動，將技術潛力轉化為永續的商業性成果。首先，他們應在藥物研發早期階段就整合發行策略，與臨床和監管團隊合作設計製劑和裝置，從而最大限度地減少後期重新設計，並加快核准准備工作。其次，他們應實現供應鏈多元化，並對替代材料和供應商進行認證，以降低關稅和地緣政治風險，同時在關鍵組件的採購中採用冗餘機制。第三，對於包括脂質奈米顆粒和奈米顆粒系統在內的複雜製劑，他們應投資於中試生產和可擴展的製程驗證，以便在產品進入III期臨床試驗時縮短大規模生產的時間。

採用可重複的混合方法研究方法，結合嚴格的第二手資料審查和對專家的直接訪談，來檢驗技術的成熟度和商業性趨勢。

本報告基於結構化的調查方法，結合了多方面的二手資料分析和有針對性的原始研究，從而確保了研究結果的可靠性、實用性和可重複性。二手資料分析包括對同行評審文獻、監管指導文件、專利申請和技術白皮書的精選審查，旨在捕捉技術趨勢、監管先例和材料科學領域的進展。透過這些二手資料分析所獲得的洞見建立了一個基本的分類系統，用於對給藥途徑、底層技術、治療應用、產品類型和最終用戶管道進行分類。

整合技術、營運和商業性需求，以確定哪些交付技術創新將在臨床實踐和市場中產生可擴展的影響。

總之，新型藥物遞送系統正從利基技術示範階段邁向決定治療差異化和病患療效的核心策略資產。先進材料、設備工程和數位健康技術的融合正在拓展標靶遞送、緩釋和微創給藥的可能性。同時，地緣政治和政策的變化，包括關稅和區域製造預期的變化，使得供應鏈的韌性和本地化成為一項戰略挑戰，影響成本結構和監管管道。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：新型藥物輸送系統市場：依產品類型分類

  • 緩釋注射藥物
    • 可生物分解
    • 不可生物分解
  • 塗藥支架
    • 冠狀動脈
    • 外圍
  • 嵌入式泵浦
    • 點滴幫浦
    • 滲透泵浦
  • 脂質奈米顆粒製劑
    • 傳統脂質奈米顆粒
    • 隱形脂質奈米顆粒
  • 微針貼片
    • 溶解度
    • 固態的

第9章：新型藥物遞送系統市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 噴霧器
  • 注射
    • 肌肉內部
    • 靜脈
    • 皮下
  • 鼻腔
    • 滴鼻劑
    • 噴
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 經皮
    • 凝膠
    • 修補

第10章：新型藥物輸送系統市場：依技術分類

  • 水凝膠
    • 自然的
    • 合成
  • 植入
    • 可生物分解
    • 不可生物分解
  • 微型針
    • 覆蓋類型
    • 溶解度
    • 中空的
    • 固體的
  • 奈米顆粒
    • 樹狀聚合物
    • 脂質奈米顆粒
      • 陽離子脂質奈米顆粒
      • 隱形脂質奈米顆粒
    • 聚合物奈米粒子
    • 固體脂質奈米顆粒

第11章：新型藥物傳輸系統市場：依應用領域分類

  • 循環系統
    • 支架
    • 經導管裝置
  • 內分泌學
    • 糖尿病管理
    • 荷爾蒙補充療法
  • 感染疾病
    • 抗生素輸送
    • 抗病毒藥物遞送
    • 疫苗接種
  • 神經病學
    • 中樞神經系統疾病
    • 周邊疾病
  • 腫瘤學
    • 化療
    • 免疫療法
    • 標靶治療
  • 眼科
    • 眼藥水
    • 眼內植入

第12章：新型藥物輸送系統市場：依最終用戶分類

  • 門診治療
  • 診所
  • 居家照護
  • 醫院
  • 藥局

第13章：新型藥物輸送系統市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：新型藥物遞送系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：新型藥物輸送系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國新型藥物傳輸系統市場

第17章：中國新型藥物輸送系統市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galen Limited
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Samyang Holdings Corporation
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-02026C4CB9B9

The Novel Drug Delivery Systems Market was valued at USD 16.40 billion in 2025 and is projected to grow to USD 17.95 billion in 2026, with a CAGR of 9.57%, reaching USD 31.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.40 billion
Estimated Year [2026] USD 17.95 billion
Forecast Year [2032] USD 31.13 billion
CAGR (%) 9.57%

A comprehensive orientation to how multidisciplinary innovation and patient-centric design are redefining the purpose and opportunity of novel drug delivery platforms

The landscape of drug delivery is undergoing a fundamental redefinition as molecular innovation converges with advanced materials science and patient-centric care models. Novel drug delivery systems encompass a broad array of platforms-from inhalation devices and injectable formats to transdermal patches and cutting-edge micro- and nano-scale carriers-each engineered to enhance therapeutic index, adherence, and targeted biodistribution. This executive summary synthesizes the critical technological, regulatory, and commercial inflection points that are shaping development priorities and investment strategies across biopharma, medtech, and specialty device companies.

Across therapeutic areas, developers are prioritizing delivery as an integral component of drug value rather than a peripheral enabler. This shift is driving more integrated product development lifecycles where formulation scientists, device engineers, and clinical teams co-design solutions to meet complex safety, stability, and usability requirements. Moreover, the growing emphasis on outpatient care and at-home administration is reshaping product specifications and supply chain considerations. As a result, stakeholders who can align scientific innovation with real-world usability and reimbursement pathways will have a decisive advantage in commercializability and patient uptake.

How precision targeting, digital integration, and strategic partnerships are remapping clinical value creation and commercialization pathways in advanced delivery

Several transformative shifts are accelerating the evolution of drug delivery and redefining what success looks like for new therapeutic modalities. First, precision targeting-enabled by nanoparticles, liposomal systems, and implantable devices-has advanced from proof-of-concept to practical clinical application, enabling higher therapeutic concentrations at disease sites while reducing systemic exposure. This technical maturation coincides with regulatory receptivity to combination products and novel excipients, which permits more ambitious formulations and integrated device solutions.

Concurrently, digital health integration is changing the expectations for adherence monitoring and dose personalization. Smart implants, connected infusion pumps, and sensor-integrated patches are moving delivery systems from passive carriers to active participants in care pathways. The commercial landscape is also shifting: strategic partnerships between pharmaceutical firms and specialty device companies are more common, reflecting recognition that complementary expertise is required to navigate complex development, manufacturing, and lifecycle management challenges. Taken together, these dynamics are producing a landscape where cross-functional collaboration, regulatory agility, and supply chain resilience determine which innovations scale into meaningful clinical and commercial outcomes.

Operational and strategic consequences of the United States tariff adjustments in 2025 that reshaped sourcing, manufacturing localization, and supply chain resilience

The tariff environment in the United States in 2025 introduced nuanced operational and strategic pressures across the life sciences supply chain, with variable effects on component sourcing, manufacturing location decisions, and cost structures. Tariff measures targeting specific raw materials and device components increased import costs for certain polymers, specialized lipids, and electronic subsystems used in connected devices. This change prompted an operational reassessment among manufacturers who had previously relied on globalized, cost-optimized sourcing strategies.

In response, many organizations accelerated localization of critical supply chains or established dual-sourcing arrangements to mitigate exposure to tariff volatility. Raising procurement and manufacturing visibility became a priority, as did increased investment in supply chain analytics to model tariff sensitivity across product portfolios. Importantly, these adjustments have implications beyond near-term cost management: decisions to regionalize production, qualify alternative materials, or redesign device architectures are influencing regulatory submission strategies and time-to-market calculations. Companies that proactively integrated tariff scenario planning into their commercialization roadmaps were better positioned to preserve margin and continuity of supply while maintaining development timelines.

Actionable segmentation intelligence linking routes of administration, enabling technologies, therapeutic applications, product typologies, and end-user channels for precise strategic targeting

Segment-level dynamics reveal differentiated opportunities and technical constraints that should inform R&D prioritization and commercial planning. When considering route of administration, inhalation platforms-encompassing dry powder inhalers and nebulizers-are being redeveloped to support biologics and localized pulmonary therapies, while injectable formats, including intramuscular, intravenous, and subcutaneous variants, remain central for systemic biologics and long-acting depot approaches. Nasal delivery through drops and sprays offers a compelling route for rapid CNS and mucosal immunization strategies, and oral delivery across capsules, liquids, and tablets continues to be optimized for stability and patient adherence. Transdermal options, realized through gels and patches, are increasingly attractive for chronic, steady-state therapies and for therapies requiring steady plasma profiles.

From a technology perspective, hydrogels-both natural and synthetic-are maturing as sustained-release matrices, whereas implants, whether biodegradable or nonbiodegradable, support long-duration local therapies and reduced dosing frequency. Microneedles in coated, dissolvable, hollow, and solid formats provide minimally invasive delivery with potential for self-administration, and nanoparticle platforms, including dendrimers, various liposome classes, polymeric nanoparticles, and solid lipid nanoparticles, enable targeted delivery and controlled release. Application-driven segmentation illuminates where clinical need and commercialization potential intersect: cardiovascular interventions that leverage stents and transcatheter devices, endocrinology solutions focused on diabetes management and hormone therapies, infectious disease delivery channels for antibiotics, antivirals, and vaccines, neurology approaches for central and peripheral disorders, oncology delivery systems for chemotherapy, immunotherapy, and targeted agents, and ophthalmology solutions spanning eye drops to ocular implants.

Product-type distinctions further refine go-to-market considerations: depot injections, both biodegradable and nonbiodegradable, offer adherence advantages; drug-eluting stents for coronary and peripheral use require procedural integration; implantable pumps such as infusion and osmotic pumps demand durable power and control solutions; liposomal formulations-standard and stealth variants-affect pharmacokinetics and immunogenicity; and microneedle patches, in dissolvable and solid forms, present unique manufacturing scale-up pathways. Finally, end-user segmentation spanning ambulatory care, clinics, home care, hospitals, and pharmacies defines distribution models, training requirements, and reimbursement touchpoints. Integrating these segmentation lenses enables nuanced product design and market-entry sequencing that align technical feasibility with clinical adoption pathways.

How regional regulatory, reimbursement, and manufacturing landscapes across the Americas, EMEA, and Asia-Pacific influence development priorities and market entry sequencing

Regional dynamics shape prioritization for development, manufacturing, and commercialization of novel delivery systems. In the Americas, innovation clusters in device-enabled biologics and implantable technologies coexist with advanced reimbursement frameworks that can accelerate adoption, but supply chain and tariff considerations necessitate localized manufacturing and regulatory alignment. Europe, Middle East & Africa displays heterogeneity: established regulatory pathways and centralized procurement in some European markets can favor advanced devices and combination products, while emerging markets within the region may prioritize cost-effective, easy-to-administer solutions and decentralized care models. Asia-Pacific presents diverse opportunities driven by large patient populations, expanding clinical trial capacity, and rapid industrial scale-up capabilities, but market entry requires careful navigation of country-specific regulatory nuances and local manufacturing expectations.

These regional contours influence partner selection, clinical development strategies, and commercialization sequencing. For example, companies may prioritize pilot launches in markets with favorable reimbursement policies and strong specialty channel access before expanding into regions where price sensitivity or procurement processes demand alternative value propositions. Similarly, regulatory engagement strategies should reflect regional differences in device and biologic governance, with early dialogue enabling feasibility assessments and pathway optimization. Balancing a global vision with regionalized execution plans is essential to capture adoption momentum while managing operational complexity.

Competitive differentiation driven by integrated technology stacks, strategic collaborations, and a focus on real-world evidence and manufacturing excellence

Competitive dynamics in novel drug delivery systems are characterized by a mix of established pharmaceutical companies, device specialists, and nimble technology innovators. Leading organizations are differentiating through vertically integrated capabilities that span formulation science, device engineering, and manufacturing scale-up, enabling accelerated translation from concept to clinic. Strategic collaborations-ranging from licensing and co-development agreements to equity investments-are common pathways for obtaining complementary competencies, particularly in areas such as nanoparticle engineering, microneedle fabrication, and digital health integration.

Intellectual property remains a central pillar of competitive advantage, as strong patent families around core materials, delivery mechanisms, and device interfaces can create meaningful barriers to entry. However, commercialization success increasingly depends on real-world evidence generation, user-centric design validation, and payer engagement to establish differentiated value. Companies that invest in robust post-market surveillance, adherence analytics, and clinical outcomes studies will be better positioned to defend pricing and expand indications. Manufacturing excellence and regulatory track record are additional differentiators; partners and acquirers favor organizations with demonstrated ability to scale complex biologic formulations, maintain sterility assurance, and navigate combination product submissions efficiently.

Practical and prioritized strategic actions for life sciences leaders to align R&D, supply chain resilience, and commercial evidence generation for sustainable adoption

Industry leaders should adopt a set of prioritized actions to convert technical promise into sustainable commercial outcomes. First, embed delivery strategy early in drug development by co-designing formulations and devices with clinical and regulatory teams, thereby minimizing late-stage redesigns and accelerating approval-readiness. Second, diversify supply chains and qualify alternate materials and vendors to mitigate tariff and geopolitical risks while building redundancy into critical component sourcing. Third, invest in pilot manufacturing and scalable process validation for complex formulations, including liposomal and nanoparticle systems, to reduce time-to-scale when a product advances to pivotal studies.

Additionally, establish strategic partnerships to access complementary capabilities such as microneedle fabrication, implantable device engineering, or digital adherence technologies, and structure agreements to balance risk and upside. Strengthen value demonstration by designing outcomes-based evidence programs that align clinical endpoints with payer requirements and end-user benefits such as reduced hospital visits or improved adherence. Finally, prioritize human factors and training programs to ensure that novel devices and administration routes are intuitive for clinicians and patients, thereby smoothing adoption curves in ambulatory and home-care settings. These integrated actions will improve the likelihood of clinical success and commercial uptake while protecting margin and accelerating patient access.

A reproducible mixed-methods research approach combining rigorous secondary review and expert primary interviews to validate technology readiness and commercial dynamics

This report is grounded in a structured research methodology that blends multi-source secondary analysis with targeted primary inquiry to ensure the findings are robust, actionable, and reproducible. Secondary research included curated reviews of peer-reviewed literature, regulatory guidance documents, patent filings, and technical white papers to map technological trends, regulatory precedents, and materials science advancements. These secondary insights established the foundational taxonomy used to segment routes of administration, enabling technologies, therapeutic applications, product types, and end-user channels.

Primary research involved in-depth interviews with cross-functional stakeholders, including formulation scientists, device engineers, regulatory affairs specialists, clinical investigators, manufacturing leaders, and commercial executives. These conversations validated technical feasibility assessments, surfaced practical barriers to adoption, and clarified procurement and reimbursement dynamics across regions. Quantitative validation checks were performed through triangulation of interview inputs against secondary sources and technology readiness indicators. Finally, internal subject-matter experts synthesized the evidence into scenario analyses and strategic recommendations, with iterative review cycles to address potential bias and ensure clarity for decision-makers.

Synthesis of technological, operational, and commercial imperatives that will determine which delivery innovations translate into scalable clinical and market impact

In conclusion, novel drug delivery systems are transitioning from niche technical demonstrations to core strategic assets that determine therapeutic differentiation and patient outcomes. The convergence of advanced materials, device engineering, and digital health capabilities is expanding what is possible in targeted delivery, sustained release, and minimally invasive administration. At the same time, geopolitical and policy shifts, including tariff changes and regional manufacturing expectations, have made supply chain resilience and localization strategic imperatives that influence both cost structures and regulatory pathways.

To capture the full upside of these trends, organizations must integrate delivery considerations across the product lifecycle, prioritize partnerships to fill capability gaps, and invest in real-world evidence that resonates with payers and clinicians. Those who align scientific ingenuity with pragmatic commercialization planning-ensuring manufacturing readiness, regulatory foresight, and user-centric design-will accelerate adoption and deliver measurable improvements in care. The opportunities are significant, but realizing them requires coordinated action across R&D, operations, and commercial functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Novel Drug Delivery Systems Market, by Product Type

  • 8.1. Depot Injections
    • 8.1.1. Biodegradable
    • 8.1.2. Nonbiodegradable
  • 8.2. DrugEluting Stents
    • 8.2.1. Coronary
    • 8.2.2. Peripheral
  • 8.3. Implantable Pumps
    • 8.3.1. Infusion Pumps
    • 8.3.2. Osmotic Pumps
  • 8.4. Liposomal Formulations
    • 8.4.1. Conventional Liposomes
    • 8.4.2. Stealth Liposomes
  • 8.5. Microneedle Patches
    • 8.5.1. Dissolvable
    • 8.5.2. Solid

9. Novel Drug Delivery Systems Market, by Route Of Administration

  • 9.1. Inhalation
    • 9.1.1. Dry Powder Inhalers
    • 9.1.2. Nebulizers
  • 9.2. Injectable
    • 9.2.1. Intramuscular
    • 9.2.2. Intravenous
    • 9.2.3. Subcutaneous
  • 9.3. Nasal
    • 9.3.1. Drops
    • 9.3.2. Sprays
  • 9.4. Oral
    • 9.4.1. Capsules
    • 9.4.2. Liquids
    • 9.4.3. Tablets
  • 9.5. Transdermal
    • 9.5.1. Gels
    • 9.5.2. Patches

10. Novel Drug Delivery Systems Market, by Technology

  • 10.1. Hydrogels
    • 10.1.1. Natural
    • 10.1.2. Synthetic
  • 10.2. Implants
    • 10.2.1. Biodegradable
    • 10.2.2. Nonbiodegradable
  • 10.3. Microneedles
    • 10.3.1. Coated
    • 10.3.2. Dissolvable
    • 10.3.3. Hollow
    • 10.3.4. Solid
  • 10.4. Nanoparticles
    • 10.4.1. Dendrimers
    • 10.4.2. Liposomes
      • 10.4.2.1. Cationic Liposomes
      • 10.4.2.2. Stealth Liposomes
    • 10.4.3. Polymeric Nanoparticles
    • 10.4.4. Solid Lipid Nanoparticles

11. Novel Drug Delivery Systems Market, by Application

  • 11.1. Cardiovascular
    • 11.1.1. Stents
    • 11.1.2. Transcatheter Devices
  • 11.2. Endocrinology
    • 11.2.1. Diabetes Management
    • 11.2.2. Hormone Replacement
  • 11.3. Infectious Diseases
    • 11.3.1. Antibiotic Delivery
    • 11.3.2. Antiviral Delivery
    • 11.3.3. Vaccine Delivery
  • 11.4. Neurology
    • 11.4.1. CNS Disorders
    • 11.4.2. Peripheral Disorders
  • 11.5. Oncology
    • 11.5.1. Chemotherapy
    • 11.5.2. Immunotherapy
    • 11.5.3. Targeted Therapy
  • 11.6. Ophthalmology
    • 11.6.1. Eye Drops
    • 11.6.2. Ocular Implants

12. Novel Drug Delivery Systems Market, by End User

  • 12.1. Ambulatory Care
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals
  • 12.5. Pharmacies

13. Novel Drug Delivery Systems Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Novel Drug Delivery Systems Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Novel Drug Delivery Systems Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Novel Drug Delivery Systems Market

17. China Novel Drug Delivery Systems Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Baxter International Inc.
  • 18.9. Becton, Dickinson and Company
  • 18.10. Boston Scientific Corporation
  • 18.11. Eli Lilly and Company
  • 18.12. F. Hoffmann-La Roche Ltd.
  • 18.13. Galen Limited
  • 18.14. Gilead Sciences, Inc.
  • 18.15. GlaxoSmithKline plc
  • 18.16. Johnson & Johnson
  • 18.17. Merck & Co., Inc.
  • 18.18. Novartis AG
  • 18.19. Otsuka Pharmaceutical Co., Ltd.
  • 18.20. Pfizer Inc.
  • 18.21. Regeneron Pharmaceuticals, Inc.
  • 18.22. Samyang Holdings Corporation
  • 18.23. Sanofi S.A.
  • 18.24. Takeda Pharmaceutical Company Limited
  • 18.25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OSMOTIC PUMPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OSMOTIC PUMPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OSMOTIC PUMPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCINE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCINE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCINE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CNS DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CNS DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OCULAR IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OCULAR IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OCULAR IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 260. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2032 (USD MILLION)
  • TABLE 261. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 263. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 265. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 267. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2032 (USD MILLION)
  • TABLE 269. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 270. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2032 (USD MILLION)
  • TABLE 271. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 272. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 273. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 275. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 284. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2032 (USD MILLION)
  • TABLE 286. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2032 (USD MILLION)
  • TABLE 288. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 290. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2032 (USD MILLION)
  • TABLE 292. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)

TABLE